Globus Medical Posts 3Q EPS of $1.04
GMED sits 35% above its 52-week low of $60.255 on elevated volume (2.4× avg).
Summary
Globus Medical reported third-quarter EPS of $1.04, with adjusted EPS of $1.23, on sales of $763.7M and net income of $141.2M. That compares with diluted EPS of $1.10 in Q2 2026, when revenue rose 5.9% to $789.6M and operating income more than doubled to $182.4M. The headline gives only the EPS line, so margins and any guidance update are not yet in hand. The print lands two days after the company closed its acquisition of Synaptive Medical, adding cranial neurosurgery robotics, and follows the August deal for Higgs Boson Health. Full quarterly detail will determine whether the Q2 margin improvement held.
At the time of this announcement, GMED was trading at $81.52 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $60.26 to $101.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.